Denkert et al. investigated 2310 HER2-negative BC patients receiving neoadjuvant chemotherapy, and found that approximately 60% of hormone receptor (HR) positive BC patients also had low HER2 expression compared to 33% of triple negative breast cancer (TNBC) patients [11]. This evidence concerns the gene ERBB2 and breast cancer.